News Releases

All Releases
View Summary OncoGenex Regains Rights to Custirsen from Teva
Apr 27, 2015
PDF 14.3 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Apr 9, 2015
PDF 10.6 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014
Mar 26, 2015
PDF 21.7 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015
Mar 23, 2015
PDF 10.8 KB Add to Briefcase
View Summary OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
Feb 24, 2015
PDF 17.4 KB Add to Briefcase
View Summary OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years
Feb 12, 2015
PDF 11.8 KB Add to Briefcase
View Summary OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Jan 16, 2015
PDF 57.7 KB Add to Briefcase
View Summary OncoGenex to Regain Rights to Custirsen from Teva
Dec 30, 2014
PDF 60.0 KB Add to Briefcase
View Summary OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer
Dec 19, 2014
PDF 17.1 KB Add to Briefcase
View Summary OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
Dec 16, 2014
PDF 16.1 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
Nov 17, 2014
PDF 9.2 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
Oct 30, 2014
PDF 17.9 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
Oct 16, 2014
PDF 9.6 KB Add to Briefcase
View Summary OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
Sep 16, 2014
PDF 12.6 KB Add to Briefcase
View Summary OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
Aug 21, 2014
PDF 12.7 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014
Aug 7, 2014
PDF 18.1 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Aug 7, 2014
PDF 9.9 KB Add to Briefcase
View Summary OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014
Jul 24, 2014
PDF 9.6 KB Add to Briefcase
View Summary OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment
Jul 1, 2014
PDF 14.6 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering
Jun 26, 2014
PDF 10.4 KB Add to Briefcase
Showing 41-60 of 385 Page: 1 2 3 4 5 6 7 ... 20  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase